City Therapeutics is at the forefront of developing next-generation RNA interference (RNAi) therapeutics, focusing on engineering small interfering RNAs (siRNAs) to enhance the efficacy and reach of RNAi-based medicines. The company aims to unlock the transformative potential of RNAi by creating innovative trigger molecules that can effectively silence gene expression and block protein production. Their approach includes designing siRNAs with improved characteristics such as smaller size, novel cleavage mechanisms, and enhanced potency and specificity. This engineering platform is intended to address a wide range of diseases, particularly those where RNAi therapeutics can offer significant advantages over traditional treatment modalities like small molecules and antibodies.

In addition to developing better trigger molecules, City Therapeutics is also focused on improving the delivery of RNAi therapeutics through the use of tailored targeting ligands. These ligands are designed to facilitate the robust delivery of RNAi medicines to various cell types and tissues, thereby expanding the therapeutic applications of RNAi technology. The company leverages advancements in human genetics to identify both novel and validated therapeutic targets, optimizing their clinical development processes to maximize patient impact. With a leadership team comprised of pioneers in the RNAi field, City Therapeutics is committed to advancing a pipeline of RNAi-based medicines that promise to make a significant difference in multiple therapeutic areas.

United States

Founded by pioneering executives and scientists in RNAi, City Therapeutics is advancing next-generation engineering of small interfering RNAs (siRNAs) – the “trigger” molecules that mediate RNAi – to improve and expand the reach of RNAi-based medicines. City’s mission is to build the leading next-generation RNAi therapeutics company, unlocking RNAi’s transformative potential to help patients with a wide range of diseases.

City Therapeutics

Company Details